| Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes PV Nuzzo, JE Berchuck, K Korthauer, S Spisak, AH Nassar, S Abou Alaiwi, ... Nature medicine 26 (7), 1041-1043, 2020 | 214 | 2020 |
| Prostate cancer reactivates developmental epigenomic programs during metastatic progression MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ... Nature genetics 52 (8), 790-799, 2020 | 184 | 2020 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 104 | 2021 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature communications 12 (1), 1979, 2021 | 90 | 2021 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 89 | 2021 |
| Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer P Cejas, Y Xie, A Font-Tello, K Lim, S Syamala, X Qiu, AK Tewari, N Shah, ... Nature communications 12 (1), 5775, 2021 | 76 | 2021 |
| Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020 | 71 | 2020 |
| Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors S Abou Alaiwi, AH Nassar, W Xie, Z Bakouny, JE Berchuck, DA Braun, ... Cancer immunology research 8 (8), 1075-1084, 2020 | 69* | 2020 |
| Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer outcomes study AL Schmidt, Z Bakouny, S Bhalla, JA Steinharter, DA Tremblay, MM Awad, ... Cancer cell 38 (6), 769-770, 2020 | 63 | 2020 |
| CDKN2A Alterations and Response to Immunotherapy in Solid Tumors E Adib, AH Nassar, EW Akl, S Abou Alaiwi, PV Nuzzo, TH Mouhieddine, ... Clinical Cancer Research 27 (14), 4025-4035, 2021 | 62 | 2021 |
| Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors AH Nassar, E Adib, S Abou Alaiwi, T El Zarif, S Groha, EW Akl, PV Nuzzo, ... Cancer Cell 40 (10), 1161-1172. e5, 2022 | 57 | 2022 |
| Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma AH Nassar, S Abou Alaiwi, SH AlDubayan, N Moore, KW Mouw, ... Genetics in Medicine 22 (4), 709-718, 2020 | 57 | 2020 |
| Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma BA McGregor, AKA Lalani, W Xie, JA Steinharter, ZE Bakouny, DJ Martini, ... European Journal of Cancer 135, 203-210, 2020 | 55 | 2020 |
| Germline variants associated with toxicity to immune checkpoint blockade S Groha, SA Alaiwi, W Xu, V Naranbhai, AH Nassar, Z Bakouny, T El Zarif, ... Nature medicine 28 (12), 2584-2591, 2022 | 48 | 2022 |
| Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology E Adib, AH Nassar, S Abou Alaiwi, S Groha, EW Akl, LM Sholl, ... Genome Medicine 14 (1), 39, 2022 | 38 | 2022 |
| CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer E Adib, T El Zarif, AH Nassar, EW Akl, S Abou Alaiwi, TH Mouhieddine, ... British journal of cancer 126 (5), 797-803, 2022 | 26 | 2022 |
| Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study NM Chanza, W Xie, M Issa, H Dzimitrowicz, A Tripathi, B Beuselinck, ... Journal for immunotherapy of cancer 8 (1), 2020 | 25* | 2020 |
| The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response JE Berchuck, E Adib, S Abou Alaiwi, AK Dash, JN Shin, D Lowder, ... Cancer research 82 (16), 2848-2859, 2022 | 21 | 2022 |
| Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study Z Bakouny, C Labaki, S Bhalla, AL Schmidt, JA Steinharter, J Cocco, ... Annals of Oncology 33 (8), 836-844, 2022 | 21 | 2022 |
| A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer S Tang, V Sethunath, NY Metaferia, MF Nogueira, DS Gallant, ER Garner, ... Cell reports 38 (8), 2022 | 21 | 2022 |
